Distinct & Common Neural Correlates of Fear Disorders, OCD, & Eating Disorders

描述（由申请人提供）：精神障碍可以可靠地诊断，但大脑功能障碍如何导致临床症状尚不清楚。正如NIMH战略计划所认识到的那样，迫切需要在诊断中研究多种潜在的脑回路，以确定具有共同神经功能障碍的患者群体。这种方法的最终目标是利用脑功能障碍作为临床诊断的辅助手段，指导治疗方法的选择和发展。与此方法一致，这个为期3年的R01应用程序建议使用经过良好验证的神经行为任务来检查三种精神疾病的多个大脑系统：社交焦虑症（SAD），强迫症（OCD）和神经性厌食症（AN）。尽管临床上不同，但这些疾病都有围绕非理性恐惧组织的适应不良行为的特征。此外，这些疾病之间的关系也备受争议。每种疾病都与不同的脑系统有关：SAD的皮质-杏仁核回路，OCD的额-纹状体-苍白质回路，AN的皮质-中脑边缘回路。该研究团队拥有使用经过验证的神经行为任务来评估这些不同神经系统功能的经验，以及招募和评估所有三种类型患者所需的临床专业知识。具体来说，该项目将使用以下神经行为任务研究180名参与者（40名SAD患者，40名OCD患者，40名AN患者和60名健康对照[HC]）： 1)恐惧消退保留作为“安全”学习的衡量标准（皮质-杏仁核功能的探测）；2)脉冲前抑制作为感觉运动门控的测量（皮质-纹状体-苍白球功能的探针）；3)延迟折扣作为延迟满足能力的测量（皮质-中边缘功能的探测）。所有180名参与者将完成所有三项任务和详细的临床评估。这项工作将在三年内完成，从而能够迅速评价这一办法的成功。目标是：1)正如试点数据所显示的那样，确定每种疾病都与其中一项任务的特定异常有关；2)确定这些异常是特异性的还是与其他疾病共有的；3)探索反应模式是否与维度特征、临床特征或跨疾病病例的新分组有关。如果任务表现像假设的那样与特定的疾病有关，那么数据将支持特定神经系统在这些疾病中的作用，以及将每个任务用作该疾病的神经行为标记。未来的研究将证实这些任务的神经相关性，扩展它们的特异性，并建立它们的临床应用。与NIMH的RDoC倡议一致，目标是使用非侵入性神经行为探针阐明这些不同疾病背后的脑功能障碍。反过来，这可以成为新的诊断方法的基础，以帮助指导，甚至可能开发新的治疗方法。

DESCRIPTION (provided by applicant): Psychiatric disorders can be diagnosed reliably, but how dysfunction in the brain leads to clinical symptoms is unclear. As recognized by the NIMH Strategic Plan, there is an urgent need to study multiple underlying brain circuits across diagnoses with the goal of identifying groups of patients with shared neural dysfunction. The ultimate goal of this approach is to use brain dysfunction, as an adjunct to clinical diagnosis, to guide the selection and development of treatments. Consistent with this approach, this 3-year R01 application proposes to use well-validated neurobehavioral tasks to examine multiple brain systems across three psychiatric disorders: social anxiety disorder (SAD), obsessive-compulsive disorder (OCD), and anorexia nervosa (AN). Although clinically different, these disorders share the feature of maladaptive behaviors organized around irrational fears. Moreover, the relationship between these disorders is hotly debated. Each disorder has been associated with different brain systems: cortico-amygdalar circuitry in SAD, fronto-striatal-pallidal circuitry in OCD, and cortico-mesolimbic circuitry in AN. The research team has experience using well-validated neurobehavioral tasks to assess the functioning of these different neural systems and the clinical expertise needed to recruit and evaluate all three types of patients. Specifically, this project will study 180 participants (40 with SAD, 40 with OCD, 40 with AN, and 60 healthy controls [HC]) using the following neurobehavioral tasks: 1) Fear extinction retention as a measure of "safety" learning (a probe of cortico-amygdalar functioning); 2) Prepulse inhibition as a measure of sensorimotor gating (a probe of cortico-striatal-pallidal functioning); and 3) Delay discounting as a measure of capacity to delay gratification (a probe of cortical-mesolimbic functioning). All 180 participants will complete all three tasks and detailed clinical assessments. This work will be completed in three years, enabling a rapid evaluation of the success of this approach. The goals are: 1) to establish that each disorder is associated with specific abnormalities on one of these tasks, as the pilot data suggest; 2) to determine whether these abnormalities are specific or shared with the other disorders; and 3) to explore whether the pattern of responses is associated with dimensional traits, clinical features, or novel groupings of cases across disorders. If task performance is associated with specific disorders as hypothesized, the data will support the role of particular neural systems in those disorders, and the use of each task as a neurobehavioral marker in that disorder. Future studies will confirm the neural correlates of these tasks, extend their specificity, and establish their clinical utility. Consistent with the RDoC initiative of NIMH, the goal is to clarify the brain dysfunction underlying these different disorders using non-invasive neurobehavioral probes. This, in turn, can be the basis for new diagnostic approaches to help guide, and perhaps develop, new treatments.